Success Metrics

Clinical Success Rate

33.3%

Based on 3 completed trials

Completion Rate

33%(3/9)

Active Trials

0(0%)

Results Posted

133%(4 trials)

Terminated

6(67%)

Phase Distribution

Ph phase_1

56%

Ph phase_2

44%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

5(55.6%)

Phase 2Efficacy & side effects

4(44.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

3 of 9 finished

Non-Completion Rate

66.7%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(6)

Detailed Status

Terminated6

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 15 (55.6%)

Phase 24 (44.4%)

Trials by Status

completed333%

terminated667%

Recent Activity

0 active trials

Showing 5 of 9

terminatedphase_2

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

NCT00642941

terminatedphase_2

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

NCT00760929

terminatedphase_2

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

NCT00796107

completedphase_1

A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer

NCT00882674

completedphase_1

A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

NCT00400361

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT00642941Phase 2

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

Terminated

NCT00760929Phase 2

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

Terminated

NCT00796107Phase 2

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Terminated

NCT00882674Phase 1

A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer

Completed

NCT00400361Phase 1

A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

Completed

NCT00811993Phase 1

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Terminated

NCT00985374Phase 1

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Terminated

NCT00560144Phase 1

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Completed

NCT00773383Phase 2

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Terminated

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9